Mahrukh Huseni is a prominent inventor based in Union City, CA (US). He has made significant contributions to the field of cancer therapeutics, holding a total of 4 patents. His work focuses on developing innovative solutions for cancer treatment, showcasing his dedication to improving patient outcomes.

Latest Patents

Huseni's latest patents include groundbreaking advancements such as anti-C-C motif chemokine receptor 8 (CCR8) antibodies and methods of use. This patent provides anti-CCR8 antibodies, along with compositions and methods for their preparation and application. Another notable patent is centered on diagnostic and therapeutic methods for cancer. This invention outlines diagnostic methods, therapeutic approaches, and compositions for treating various types of cancer, including kidney, lung, bladder, liver, ovarian, and breast cancers. The invention is based on the discovery that expression levels of specific biomarkers in cancer patients can predict the therapeutic efficacy of treatments involving VEGF antagonists and PD-L1 axis binding antagonists.

Career Highlights

Mahrukh Huseni is currently employed at Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. His work at Genentech has allowed him to further his research and contribute to the advancement of cancer therapies.

Collaborations

Huseni collaborates with talented professionals in his field, including Priti Hegde and Gautham Gampa. These collaborations enhance the research and development of effective cancer treatments.

Conclusion

Mahrukh Huseni's contributions to cancer therapeutics through his patents and work at Genentech highlight his commitment to innovation in the medical field. His research continues to pave the way for advancements in cancer treatment, ultimately benefiting patients worldwide.

This text is generated by artificial intelligence and may not be accurate.